Informações:
Falhas:
ID
15956
Descrição
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX); ODM derived from: https://clinicaltrials.gov/show/NCT02304354
Link
https://clinicaltrials.gov/show/NCT02304354
Palavras-chave
Versões (1)
- 21/06/2016 21/06/2016 -
Transferido a
21 de junho de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Rheumatoid Arthritis NCT02304354
Eligibility Rheumatoid Arthritis NCT02304354
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT02304354
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Rheumatoid Arthritis
Item
ra according to the american college of rheumatology (acr) criteria
boolean
C0003873 (UMLS CUI [1])
Therapeutic procedure adalimumab
Item
treatment with adalimumab in accordance to the spc
boolean
C0087111 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
C1122087 (UMLS CUI [1,2])
Antirheumatic Drugs, Disease-Modifying
Item
disease modifying anti rheumatic drugs (dmards) prescribed since 3 months and stable 4 weeks before enrollment and during 16 weeks.
boolean
C0242708 (UMLS CUI [1])
Informed consent
Item
signed consent
boolean
C0021430 (UMLS CUI [1])
anti-tumor necrosis factor therapy failed | Absent
Item
no anti tnf-alpha failure
boolean
C0281481 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C0332197 (UMLS CUI [2])
C0231175 (UMLS CUI [1,2])
C0332197 (UMLS CUI [2])
Prior Therapy rituximab
Item
previous rituximab treatment
boolean
C1514463 (UMLS CUI [1,1])
C0393022 (UMLS CUI [1,2])
C0393022 (UMLS CUI [1,2])
Medical contraindication adalimumab | Medical contraindication Methotrexate | Medical contraindication Methylprednisolone
Item
contraindication to adalimumab, methotrexate or methylprednisolone
boolean
C1301624 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0025677 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C0025815 (UMLS CUI [3,2])
C1122087 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0025677 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C0025815 (UMLS CUI [3,2])
Therapy naive Methotrexate
Item
methotrexate-naive patient
boolean
C0919936 (UMLS CUI [1,1])
C0025677 (UMLS CUI [1,2])
C0025677 (UMLS CUI [1,2])
Hematological Disease Affecting Lymphocyte | Hematological Disease Affecting Lymphoma
Item
any hematologic disease affecting the lymphocytes (in particular lymphomas)
boolean
C0018939 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0024264 (UMLS CUI [1,3])
C0018939 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0024299 (UMLS CUI [2,3])
C0392760 (UMLS CUI [1,2])
C0024264 (UMLS CUI [1,3])
C0018939 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0024299 (UMLS CUI [2,3])
Disease osteoarticular Interferes with research results | rituximab | Rheumatoid Arthritis
Item
any osteo-articular disease which could interfere with the interpretation of the influence of the rituximab on ra
boolean
C0012634 (UMLS CUI [1,1])
C0729915 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0683954 (UMLS CUI [1,4])
C0393022 (UMLS CUI [2])
C0003873 (UMLS CUI [3])
C0729915 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0683954 (UMLS CUI [1,4])
C0393022 (UMLS CUI [2])
C0003873 (UMLS CUI [3])